To help facilitate access to our nation’s nearly 70,000 retail pharmacies, PBMs are actively providing information to RxOpen, a central hub created after Hurricane Katrina to help promote uniform, consistent supply-chain information for stakeholders. PBMs also are supporting policy
(Washington, D.C) — Pharmaceutical Care Management Association (PCMA) Vice President of Policy Claire Wulf Winiarek has been selected as a member of the National Academy of Social Insurance (NASI), an organization dedicated to increasing public understanding of how social insurance contributes to
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on new National Health Expenditure (NHE) data from the Centers for Medicare & Medicaid Services: The latest NHE survey shows that the retail prescription drug net price index declined
Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaiser Health News analysis has
New Research Paper Demonstrates Declining Biosimilars Prices and Increasing Health Plan Coverage (Washington, D.C.) — Pharmacy benefit managers, PBMs, support the proliferation and use of biosimilars. A robust biosimilar market will increase competition for biologic drugs and provide added choice
See topline points from the “National Survey of Seniors Regarding the Medicare Part D Prescription Drug Benefit”
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
Voices from around the nation, including small business owners and concerned citizens, have sounded the alarm on proposals targeting pharmacy benefit companies in Congress, specifically how policies would lead to increased health care costs for consumers, patients, and families, and
Unlocking an Affordable Future Unlocking an Affordable Future NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics Stop The
PBMs leverage competition between drugs to create savings for patients.
©2024 PCMA. All Rights Reserved.
